Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome
|
|
- Hester Pitts
- 6 years ago
- Views:
Transcription
1 FERTILITY AND STERILITY VOL. 69, NO. 4, APRIL 1998 Copyright 1998 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome Laure C. Morin-Papunen, M.D.,* Riitta M. Koivunen, M.D.,* Aimo Ruokonen, M.D., and Hannu K. Martikainen, M.D.* University Central Hospital of Oulu, Oulu, Finland Objective: To determine the clinical, hormonal, and biochemical effects of 4 6 months of metformin therapy in obese patients with polycystic ovary syndrome (PCOS). Design: Prospective study. Setting: The Gynecological Endocrine Unit of University Central Hospital, Oulu, Finland. Patient(s): Twenty obese patients with PCOS. Intervention(s): Patients were treated with 0.5 g of metformin three times daily for 4 6 months. Main Outcome Measure(s): Clinical symptoms, menstrual pattern, and hirsutism, as well as serum concentrations of sex steroids, sex hormone-binding globulin (SHBG), gonadotropins, and lipids were assessed during the treatment. Result(s): Eleven women (68.8% of the women with menstrual disturbances) experienced more regular cycles during therapy. No changes in hirsutism, body mass index, or blood pressure occurred. The mean testosterone level was decreased significantly after 2 months of treatment but returned to the starting level by 4 6 months. Free testosterone levels decreased significantly during the treatment. There was no significant change in the levels of other sex steroids or lipids measured at 4 6 months of treatment. Conclusion(s): Metformin therapy is well tolerated by the majority of patients and may be clinically useful, especially in obese patients with PCOS and menstrual disturbances. (Fertil Steril 1998;69: by American Society for Reproductive Medicine.) Key Words: PCOS, metformin, insulin resistance, hyperinsulinemia Received April 25, 1997; revised and accepted December 22, Metformin hydrochloride, Diformin, Leiras, Finland. * Department of Obstetrics and Gynecology. Department of Clinical Chemistry. Reprint requests: Laure C. Morin-Papunen, M.D., Department of Obstetrics and Gynecology, University Central Hospital of Oulu, Kajaanintie Oulu, Finland (FAX: ) /98/$19.00 PII S (98) Polycystic ovary syndrome (PCOS) is a disorder characterized by chronic anovulation, elevated androgen levels, signs of hyperandrogenism, enlarged cystic ovaries, and obesity. Many patients with PCOS also have metabolic disturbances, which may have important implications for long-term health (1). Both lean and obese women with PCOS show evidence of decreased insulin sensitivity (2), but insulin resistance, accompanied by compensatory hyperinsulinemia, is most marked when there is an interaction between obesity and the syndrome (1, 3). There is a strong correlation between hyperinsulinemia and hyperandrogenism (4), and it has been shown recently that insulin concentrations have a strong positive correlation with adrenal steroid secretion in hyperandrogenic patients with PCOS (5). It therefore appears that insulin resistance precedes, and may even cause, hyperandrogenism, and not the reverse (3, 6, 7). Hyperinsulinemia in patients with PCOS is often accompanied by elevated levels of total and low-density lipoprotein (LDL), cholesterol, and triglyceride (8). This lipid pattern is a well-established risk factor for coronary artery disease (9). Insulin is an atherogenic hormone, and hyperinsulinemia, independent of other factors, is a risk for the development of cardiovascular disease in diabetic and nondiabetic individuals (10, 11). Furthermore, insulin resistance and hyperinsulinemia are major risk factors for the development of noninsulin-de- 691
2 pendent diabetes mellitus (NIDDM) at a young age (3). Many treatments have been tested to alleviate the clinical symptoms of PCOS, but most of them, such as oral contraceptives and sequential progestins, do not abolish the basic problem, that is, insulin resistance. Metformin is a biguanide antihyperglycemic drug used to treat NIDDM. It lowers blood glucose mainly by increasing the intestinal use of glucose, enhancing peripheral glucose uptake, and inhibiting hepatic glucose production. It also enhances insulin sensitivity at postreceptor levels and stimulates insulin-mediated glucose disposal but does not stimulate insulin secretion (12). Velazquez et al. (13) studied 26 women with PCOS treated with metformin. Despite the short treatment period (8 weeks), they were able to show an improvement in insulin sensitivity associated with decreases in serum LH and androgens. They postulated that most of the metabolic disturbances of PCOS can be reversed by metformin, with the additional benefit of normalization of the endocrine conditions to allow regular menstrual cycles, reversal of infertility, and spontaneous pregnancy (13). In contrast, Crave et al. (14) showed that the administration of metformin in 24 obese hirsute patients had no additional benefit over the effect of a low-calorie diet in improving hyperinsulinemia and hyperandrogenism. The aim of our study was to assess in more detail the effects of long-term metformin therapy on clinical and biochemical indices in obese patients with PCOS. MATERIALS AND METHODS Patients Thirty-one women with PCOS were recruited from the Endocrinology Outpatient Clinic at the University Hospital of (Oulu, Finland). The ages of the patients varied between 20 and 41 years (mean, 30 years). Eleven women stopped the treatment after 2 months for various reasons: three underwent IVF-ET treatment, one conceived, one moved away, three had side effects (vomiting and diarrhea lasting for 2 months), two had no apparent reason, and one because she received no help for her hirsutism. Twenty women continued the treatment for 4 6 months and were included in the analysis. Regular (normal) menstrual cycles were defined as cycles with a minimum-maximum length variation of 4 days and with an intermenstrual interval between 21 and 35 days (15). Irregular cycles were those with variations of the intermenstrual interval of more than 4 days and a period of 35 days. Oligomenorrhea was defined as menstruation with an interval of 35 days and amenorrhea as the absence of periods for 6 months. The criteria for PCOS were as defined by Homburg (16). All of the patients had polycystic ovaries shown by vaginal ultrasonography ( 8 subcapsular follicles of 3 8 mm diameter in one plane in one ovary and increased stroma) and at least one of the following symptoms: oligomenorrhea or amenorrhea (13/20, 65%), hirsutism (Ferriman-Gallwey score of 7) (17) (12 of 20, 60%), or acne (7 of 20, 35%). Seventeen (85%) of the patients were obese, with a body mass index (BMI) of 27 kg/m 2. Ten of 20 (50%) had elevated serum testosterone levels ( 0.89 ng/ml). One of the patients had hypothyroidism, had used thyroxine medication before the study, and was euthyroid. After 4 months of treatment, hypothyroidism was diagnosed in one other patient. Patients were excluded if they were diabetic, smoked, used alcohol, or had received sex hormones or drugs known to affect lipoprotein metabolism during the 2 months preceding the study. A 1-mg dexamethasone suppression test was performed in hirsute and hyperandrogenic women (testosterone level of 1.5 ng/ml to exclude Cushing s syndrome. Protocol of the Study The treatment consisted of 500 mg of metformin therapy (metformin hydrochloride, Diformin; Leiras, Finland) administered three times daily. All patients were evaluated before the treatment, 18 patients were evaluated at 2 months, and all 20 were evaluated at 4 6 months. Blood pressure was measured after the patient had been sitting for 20 minutes. Transvaginal ultrasonography with a 6-MHz probe (General Electric RT-200; Milwaukee, WI) was performed to measure ovarian volumes and the number of follicles. Volume determinations were made using the formula for the volume of an ellipsoid: length width thickness (18). Venous blood samples were obtained after hours of fasting within the first week of the cycle for those patients who were menstruating or at any convenient time for amenorrheic women. An oral glucose tolerance test (OGTT) and insulin response were performed before and after metformin treatment after hours of fasting between 8 A.M. and 10 A.M. After a basal blood sample was obtained, a 75-g glucose load was administered orally. Blood samples were obtained, at 60 and 120 minutes after glucose loading for glucose and insulin determinations. Glucose tolerance was evaluated using the criteria of the World Health Organization (19). The study was approved by the Ethics Committee of the University Hospital of Oulu, Oulu, Finland, and informed written consent was obtained from each subject. Assays The concentrations of sex hormone-binding globulin (SHBG), LH, FSH, and TSH were analyzed by fluoroimmunoassays (Wallac Ltd., Turku, Finland); prolactin and free T 4 were assessed by a chemiluminescence system (Ciba Corn- 692 Morin-Papunen et al. Metformin in PCOS Vol. 69, No. 4, April 1998
3 TABLE 1 Menstrual pattern before and during metformin therapy. Patient no. Menstrual period before therapy Menstrual period during therapy 1 Oligomenorrhea Irregular 2 Oligomenorrhea Irregular 3 Regular Regular 4 Oligomenorrhea Irregular 5 Regular Regular 6 Oligomenorrhea Irregular 7 Irregular Regular 8 Oligomenorrhea Oligomenorrhea 9 Oligomenorrhea Oligomenorrhea 10 Oligomenorrhea Oligomenorrhea 11 Oligomenorrhea Irregular 12 Oligomenorrhea Irregular 13 Amenorrhea Amenorrhea 14 Irregular Regular 15 Irregular Regular 16 Amenorrhea Oligomenorrhea 17 Amenorrhea Oligomenorrhea 18 Regular Regular 19 Regular Regular 20 Amenorrhea Amenorrhea ing Diagnostics, Fernwald, Germany). Radioimmunoassays were used for DHEA, DHEAS, androstenedione, and free testosterone (Diagnostics Product Corporation, Los Angeles, CA); testosterone (Farmos Diagnostica, Orion, Turku, Finland); and serum insulin (Pharmacia, Uppsala, Sweden), following the instructions of the manufacturers. Levels of serum total cholesterol, triglycerides, highdensity lipoprotein cholesterol (HDL), and blood glucose were determined by standard methods. The serum LDL level was calculated with the Friedewald formula if the serum triglyceride level was 354 mg/dl; if the triglyceride level was 354 mg/dl, it was precipitated by heparin in isoelectric point (LDL-cholesterol; Merck, Darmstadt, Germany). Statistical Analysis A paired Wilcoxon s nonparametric rank sum test was used to compare the means of hormonal indices. The Mann- Whitney U-test was used to compare the clinical and hormonal indices between responders and nonresponders. P values were two-tailed, with 0.05 considered the limit of statistical significance. RESULTS Menstrual Pattern Eleven women (68.8% of those with menstrual disturbances before therapy) had a change in their menstrual pattern at 4 6 months of treatment: Six oligomenorrheic women achieved irregular cycles, three women with irregular cycles achieved regular menses, and two amenorrheic women became oligomenorrheic (Table 1). We divided the patients into two groups according to menstrual changes: responders (n 11) and nonresponders (n 5). Women with regular periods were excluded from these groups. The groups did not differ from each other according to mean age, BMI, or waist-hip ratio before the treatment. Hirsutism Score, BMI, Waist-Hip Ratio, and Blood Pressure There were no significant changes in the hirsutism score, BMI (Table 2), waist-hip ratio, or blood pressure during therapy. TABLE 2 Characteristics of women with PCOS before and during metformin treatment. Characteristic Before treatment After 2 mo (n 18) After 4 6 mo (n 20) Reference range BMI (kg/m 2 ) Fasting insulin (mu/ml) * Testosterone (ng/ml) Free testosterone (pg/ml) SHBG (ng/ml) Free androgen index LH (miu/ml) FSH (miu/ml) LH/FSH OHP (ng/ml) DHEA (ng/ml) DHEAS ( g/ml) Androstenedione (ng/ml) Note. Values are means SD. * P 0.04 compared with values before treatment. P 0.03 compared with values before treatment. FERTILITY & STERILITY 693
4 TABLE 3 Serum gonadotropins, steroids, and SHBG concentrations before and during metformin treatment in the responders and nonresponders. Before treatment After 2 mo After 4 6 mo Hormone RE (n 11) NR (n 5) RE (n 10) NR (n 5) RE (n 11) NR (n 5) Reference range LH (miu/ml) FSH (miu/ml) * LH/FSH Testosterone (ng/ml) Free testosterone (pg/ml) SHBG (ng/ml) Free androgen index Androstenedione (ng/ml) OHP (ng/ml) * DHEA (ng/ml) DHEAS ( g/ml) Fasting insulin (mu/ml) Note. Values are means SD. RE responders (change in menstrual pattern), NR nonresponders (no change in menstrual pattern). Women with regular menstruation were excluded. * P 0.05 compared with values before treatment among RE. P 0.05 (NR vs. RE before treatment). P 0.05 (NR vs. RE after 6 months of treatment). P 0.05 (NR vs. RE after 2 months of treatment). Ovarian Volume The respective mean volumes of the right and left ovary were 9.3 and 9.7 cm 3 before therapy, 8.1 and 8.6 cm 3 at 2 months, and 8.1 and 7.6 cm 3 at 4 6 months of treatment. The changes were not significant. Sex Steroids and SHBG The mean testosterone level decreased significantly at 2 months but returned close to the starting level after 6 months (Table 2). The mean serum level of free testosterone was high before the treatment and decreased significantly at 4 6 months of treatment but stayed above the normal reference range (Table 2). The serum SHBG level was within normal limits at the beginning of the study and did not change significantly during metformin treatment. The mean of the free androgen index was above normal limits in the beginning of the study and did not change significantly during therapy (Table 2). The mean serum levels of 17 -hydroxyprogesterone (17-OHP), DHEA, DHEAS, and androstenedione were normal before treatment and did not change significantly during therapy. In the basal state, the serum levels of 17-OHP, DHEA, DHEAS, and free androgen index were significantly lower in the responders than in the nonresponders (Table 3). After 2 months of treatment, the serum concentrations of testosterone, free testosterone, free androgen index, DHEA, and DHEAS were significantly lower in the responders. At 4 6 months of treatment, the serum testosterone, free testosterone, free androgen index, DHEA, and androstenedione concentrations were significantly lower in the responders than in the nonresponders (Table 3). Pituitary Hormones In the basal state, the mean serum LH and FSH levels were within the normal ranges. There was no significant change in gonadotropins during the treatment in the whole study group (Table 2). However, the responders showed a significant increase in serum FSH after 4 6 months of treatment. There was no significant change in the LH level in either the responder or the nonresponder group (Table 3). The baseline level of prolactin was normal, and there was no significant change during the treatment. The serum TSH and free T 4 concentrations did not change significantly during metformin therapy. Glucose and Insulin Of the 20 patients continuing the treatment for 4 6 months, OGTT was done in 10 patients before the treatment and at 4 6 months of treatment. The results of the OGTT were normal for eight women. Two patients had impaired glucose tolerance before treatment, one of them with an elevated 60-minute value and one with an elevated 120- minute value. One of them had values within normal limits after 6 months. None of the patients had values diagnostic for NIDDM. The mean fasting insulin level obtained from all patients before treatment and at 2 and 4 6 months of treatment showed a significant decrease at 4 6 months of therapy (P 0.04) (Table 2). The mean area under the insulin curve (AUC insulin) for the OGTT decreased significantly (P 0.01) by 54% at 4 6 months of treatment. At 4 6 months, we could not find any significant correlation between the 694 Morin-Papunen et al. Metformin in PCOS Vol. 69, No. 4, April 1998
5 decrease in serum fasting insulin and the changes in FSH, LH, LH/FSH, 17-OHP, DHEA, DHEAS, androstenedione, free androgen index, testosterone, and free testosterone. There was no significant difference in the fasting insulin concentrations between responders and nonresponders before treatment or at 2 or 4 6 months of treatment. Lipids The serum cholesterol, HDL, LDL, and triglyceride concentrations were within normal ranges before the treatment and did not change significantly during the study. DISCUSSION To our knowledge, this is the first study in which metformin has been administered for as long as 6 months, allowing evaluation of the clinical value of this therapy in patients with PCOS. The most important change was seen in the menstrual pattern during metformin therapy. Up to 70% of the women with menstrual disturbances achieved more regular menstruation with metformin (responders). A similar effect was seen in the study by Velazquez et al. (13), in which 7 (27%) of the 26 patients resumed normal menses and 3 became pregnant. Unfortunately, we could not assess how many of the cycles were ovulatory during therapy. However, spontaneous menstruation is psychologically important for the patient because it implies better ovarian function. In addition, the more frequent occurrence of menses in these patients may alleviate the known risks of endometrial hyperplasia and carcinoma in obese patients with PCOS (20). Despite these apparently durable clinical effects, the serum testosterone level returned close to the starting value after 6 months of treatment, after being transiently decreased at 2 months of therapy. These changes were also observed in another recent study (14). Hence, the metformin effect may be to some extent transitional, and some adaptation may occur during more prolonged therapy. The hirsutism score did not change during the treatment. There was no change in the level of 17-OHP during metformin treatment. In this study, nonresponders had higher 17-OHP levels than responders did before treatment. This is in contrast to a recent study (21), in which metformin produced a significant decrease in the basal and leuprolideinduced 17-OHP and testosterone levels. The investigators postulated that obese patients with PCOS may have an abnormality of intracellular insulin signaling or of P450 c17a activity in the ovary, which renders the enzyme complex more sensitive to insulin, and that amelioration of insulin resistance by metformin may return the activity of the enzyme to normal (21). The reason for this discrepancy remains uncertain, but it may be due to the difference in the patient populations; our patients were less obese. It is possible that the hypersensitivity of ovarian cytochrome P450 to insulin in patients with PCOS may appear only in those with more severe obesity. After 4 6 months of treatment, there was a significant decrease in the levels of fasting insulin and in the AUC insulin in the OGTT, as reported previously in some (13, 21), but not in all (22, 23) studies. However, because OGTT was performed for only five women from the responder group and for two women from the nonresponder group, it was not possible to compare these groups with regard to the OGTT. In this study, no change was observed in the SHBG levels during metformin treatment. Because insulin inhibits SHBG production by Hep G2 cells (24), we could have expected an increase in SHBG levels during metformin therapy, as was reported in some previous studies (13, 21). The increase in SHBG observed in an earlier study (13) was probably due to weight loss and the simultaneous improvement of insulin resistance, rather than to any effect of metformin (14). The BMI remained constant in our study, and the change in insulin secretion was obviously too small to affect SHBG production. Metformin treatment had little effect on blood lipids or blood pressure in this study. However, abnormal lipid values in some patients normalized during the treatment, which is in accordance with the results of another recent study in obese women with PCOS (13). This is in contrast to a previous report of diabetic and nondiabetic men, in whom long-term therapy with metformin resulted in a moderate reduction in plasma triglyceride and total cholesterol levels and in a small increase in plasma HDL concentrations (25). Our results support the fact that, despite the small metabolic and hormonal changes, metformin therapy is well tolerated by the majority of patients and may be clinically useful, especially in obese patients with PCOS and menstrual disturbances and in those women with PCOS who are unable to achieve and maintain a durable, diet-induced weight loss. However, the effect may be transitory with regard to testosterone levels, and women with PCOS and hirsutism did not seem to benefit from metformin therapy. Acknowledgments: We thank Tarja Bützow, M.D., of the Family Federation of Finland, Helsinki, and Professor A. Kauppila, Department of Gynecology and Obstetrics, University Hospital of Oulu, Finland, for their critical and thoughtful readings of the manuscript. References 1. Franks S. Polycystic ovary syndrome: a changing perspective. Clin Endocrinol (Oxf). 1989;31: Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance independent of obesity in polycystic ovary syndrome. Diabetes 1989;38: Dunaif A. Molecular mechanisms of insulin resistance in the polycystic ovary syndrome. Semin Reprod Endrocrinol 1994;12: FERTILITY & STERILITY 695
6 4. Burghen GA, Givens JR, Kibatchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovary syndrome. J Clin Endrocrinol Metab 1980;50: Martikainen H, Salmela P, Nuojua-Huttunen S, Perälä J, Leinonen S, Knip M, et al. Adrenal steroidogenesis is related to insulin in hyperandrogenic women. Fertil Steril 1996;66: Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinism. J Clin Endocrinol Metab 1987;65: Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Lichola T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992;41: Conway GS, Jacobs HS. Clinical implications of hyperinsulinemia in women. Clin Endocrinol (Oxf) 1993;39: Slowinski-Szrendnicka J, Zgliczynski S, Wierzbicki M. The role of hyperinsulinemia in the development of lipid disturbances in nonobese and obese women with the polycystic ovary syndrome. J Endocrinol Invest 1991;14: Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37: Wild RA. Cardiovascular disease risks, insulin resistance, and androgen excess. Semin Reprod Endocrinol 1994;12: Williams G. Management of non insulin-dependent diabetes mellitus. Lancet 1994;343: Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenism, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43: Crave JC, Fimbel S, Lejeune H, Cugnardey N, Dechaud H, Pugeat M. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 1995;80: Polson DW, Adams J, Wadsworth J, Franks S. Polycystic ovaries a common finding in normal women. Lancet 1988;1: Homburg R. Polycystic ovary syndrome from gynaecological curiosity to multisystem endocrinopathy. Hum Reprod 1996;11: Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21: Robert Y, Dubrulle F, Gaillandre L, Ardaens Y, Thomas-Desrousseaux P, Lemaitre L, et al. Ultrasound assessment of ovarian stroma hypertrophy in hyperandrogenism and ovulation disorders: visual analysis versus computerized qualification. Fertil Steril 1995;64: World Health Organization, Committee E. Second report on diabetes mellitus. Tech Rep Ser 646. Geneva: WHO, Dahlgren E, Friberg LG, Johansson S, Lindstrom B, Oden A, Samsioe G. Endometrial carcinoma. Ovarian dysfunction a risk factor in young women. Eur J Obstet Gynecol Reprod Biol 1991;41: Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17a activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996;335: Acbay Ö, Gündogdu S. Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil Steril 1996;65: Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82: Singh A, Hamilton-Fairley D, Koistinen R, Seppälä M, James VHT, Franks S, et al. Effect of insulin-like growth factor type I (IGF-I) and insulin on the secretion of sex hormone binding globulin and IGF-I binding protein (IGP-I) by human hepatoma cells. J Endocrinol 1990; 124:RI III. 25. Nestler JE, Beer NA, Jakubowitcz DJ, Beer RM. Effects of a reduction in circulating insulin by metformin on serum dehydroepiandrosterone sulfate in nondiabetic men. J Clin Endocrinol Metab 1994;78: Morin-Papunen et al. Metformin in PCOS Vol. 69, No. 4, April 1998
The prevalence of polycystic ovaries in healthy women
Acta Obstet Gynecol Scand 1999; 78: 137 141 Copyright C Acta Obstet Gynecol Scand 1999 Printed in Denmark all rights reserved Acta Obstetricia et Gynecologica Scandinavica ISSN 0001-6349 ORIGINAL ARTICLE
More informationPolycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018
Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018 Learning Objectives At the conclusion of this lecture, learners should: 1) Know the various diagnostic
More informationROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)
ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU) In 1935, Stein and Leventhal described 7 women with bilateral enlarged PCO, amenorrhea or irregular menses, infertility and masculinizing
More informationCan Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome?
www.ijpm.in www.ijpm.ir Can Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome? Ferdous Mehrabian, Maryam Afghahi Department
More informationSemih Tugrul, M.D., Tayfun Kutlu, M.D., Oya Pekin, M.D., Elif Baglam, M.D., H useyin Kıyak, M.D., and Ozay Oral, M.D.
Clinical, endocrine, and metabolic effects of acarbose, a a-glucosidase inhibitor, in overweight and nonoverweight patients with polycystic ovarian syndrome Semih Tugrul, M.D., Tayfun Kutlu, M.D., Oya
More informationEffect of troglitazone on endocrine and ovulatory performance in women with insulin resistance related polycystic ovary syndrome
FERTILITY AND STERILITY VOL. 71, NO. 2, FEBRUARY 1999 Copyright 1999 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Effect of troglitazone
More informationThe effect of metformin on hirsutism in polycystic ovary syndrome
European Journal of Endocrinology (2002) 147 217 221 ISSN 0804-4643 CLINICAL STUDY The effect of metformin on hirsutism in polycystic ovary syndrome Christopher J G Kelly and Derek Gordon Stobhill Hospital,
More informationAFTER THE FIRST publications reporting the treatment
0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(8):4593 4598 Printed in U.S.A. Copyright 2005 by The Endocrine Society doi: 10.1210/jc.2004-2283 Metformin and Weight Loss in
More informationMetformin in early pregnancy and abortions. Laure Morin-Papunen, MD, PhD Dept. of Obstetrics and Gynecology University Hospital of Oulu, Finland
Metformin in early pregnancy and abortions Laure Morin-Papunen, MD, PhD Dept. of Obstetrics and Gynecology University Hospital of Oulu, Finland PCOS and miscarriage risk Metformin and miscarriage risk
More informationPolycystic Ovary Syndrome (PCOS):
Polycystic Ovary Syndrome (PCOS): Current diagnosis and treatment Anatte E. Karmon, MD Disclosures- Anatte Karmon, MD No financial relationships to disclose 2 Objectives At the end of this presentation,
More informationCase Questions. Polycystic Ovarian Syndrome: Treatment Goals and Options. Differential Diagnosis of Hyperandrogenic Anovulation
Polycystic Ovarian Syndrome: Treatment Goals and Options Marc Cornier, MD Division of Endocrinology, Metabolism and Diabetes Colorado Center for Health and Wellness University of Colorado School of Medicine
More informationMetformin Therapy Decreases Hyperandrogenism and Ovarian Volume in Women with Polycystic Ovary Syndrome
IJMS Vol 36, No 2, June 2011 Original Article Metformin Therapy Decreases Hyperandrogenism and Ovarian Volume in Women with Polycystic Ovary Syndrome Marzieh Farimani Sanoee 1, Nosrat Neghab 1, Soghra
More informationPregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome
FERTILITY AND STERILITY VOL. 77, NO. 4, APRIL 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Pregnancies following
More informationPolycystic Ovarian Syndrome (PCOS) LOGO
Polycystic Ovarian Syndrome (PCOS) Ma qianhong Ob/Gyn Department LOGO Contents Epidemiology and Definition Pathophysiology, Endocrinological Features Diagnostic Criteria Treatment Prognosis Introduction
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome Definition: the diagnostic criteria Evidence of hyperandrogenism, biochemical &/or clinical (hirsutism, acne & male pattern baldness). Ovulatory dysfunction; amenorrhoea; oligomenorrhoea
More informationMetformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice
Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice N. D. C. Sturrock, 1 B. Lannon 2 & T. N. Fay 2 Departments of 1 Endocrinology and 2
More informationInsulin, leptin, IGF-I and insulin-dependent protein concentrations after insulin-sensitizing therapy in obese women with polycystic ovary syndrome
European Journal of Endocrinology (2001) 144 509±515 ISSN 0804-4643 CLINICAL STUDY Insulin, leptin, IGF-I and insulin-dependent protein concentrations after insulin-sensitizing therapy in obese women with
More informationNitasha Garg 1 Harkiran Kaur Khaira. About the Author
https://doi.org/10.1007/s13224-017-1082-4 ORIGINAL ARTICLE A Comparative Study on Quantitative Assessment of Blood Flow and Vascularization in Polycystic Ovary Syndrome Patients and Normal Women Using
More informationAbstract. Introduction. RBMOnline - Vol 10. No Reproductive BioMedicine Online; on web 15 November 2004
RBMOnline - Vol 10. No 1. 2005 100-104 Reproductive BioMedicine Online; www.rbmonline.com/article/1484 on web 15 November 2004 Article Metformin monotherapy in lean women with polycystic ovary syndrome
More informationClinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes
POLYCYSTIC OVARY SYNDROME Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes Ettore Guastella, M.D., a Rosa Alba Longo, M.D., b and Enrico Carmina, M.D. b a Department
More informationPolycystic Ovary Syndrome
What is the polycystic ovary syndrome? Polycystic Ovary Syndrome The polycystic ovary syndrome (PCOS) is a clinical diagnosis characterized by the presence of two or more of the following features: irregular
More informationJMSCR Vol 05 Issue 05 Page May 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i5.14 Hyperinsulinemia in Polycystic Ovary Syndrome
More information12/13/2017. Important references for PCOS. Polycystic Ovarian Syndrome (PCOS) for the Family Physician. 35 year old obese woman
Polycystic Ovarian Syndrome (PCOS) for the Family Physician Barbara S. Apgar MD, MS Professor or Family Medicine University of Michigan Ann Arbor, Michigan Important references for PCOS Endocrine Society
More informationDetermining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs)
Abstract: Determining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs) Ashraf Olabi, Ghena Alqotini College of medicine, Aleppo University Hospital Obstetrics and Gynacology, Syria.
More information16 YEAR-OLD OBESE FEMALE WITH OLIGOMENORRHEA
16 YEAR-OLD OBESE FEMALE WITH OLIGOMENORRHEA Katie O Sullivan, MD Adult/Pediatric Endocrinology Fellow University of Chicago ENDORAMA Thursday, September 4th, 2014 Disclosures No financial interests. Will
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome Kathleen Colleran, MD Professor of Medicine University of New Mexico HSC Presented for COMM-TC May 4, 2012 Objectives Understand the pathophysiology of PCOS Understand how to
More informationCREATING A PCOS TREATMENT PLAN. Ricardo Azziz, M.D., M.P.H., M.B.A. Georgia Regents University
CREATING A PCOS TREATMENT PLAN Ricardo Azziz, M.D., M.P.H., M.B.A. Georgia Regents University PCOS: CREATING A TREATMENT PLAN Good treatment plans are based on sound and complete evaluations History of
More informationPolycystic Ovary Disease: A Common Endocrine Disorder in Women
Polycystic Ovary Disease: A Common Endocrine Disorder in Women Paul Kaplan, M.D. Clinical Professor of Reproductive Endocrinology - OHSU Courtesy Senior Research Associate, Human Physiology University
More informationMetformin and Pioglitazone in Polycystic Ovarian Syndrome: A Comparative Study
The Journal of Obstetrics and Gynecology of India (September-October 2012) 62(5):551 556 DOI 10.1007/s13224-012-0183-3 ORIGINAL ARTICLE Metformin and Pioglitazone in Polycystic Ovarian Syndrome: A Comparative
More informationPCOS Awareness Symposium Atlanta September 24 th, Preventing Diabetes & Cardiovascular Disease in PCOS
PCOS Awareness Symposium Atlanta September 24 th, 2016 Preventing Diabetes & Cardiovascular Disease in PCOS Katherine Sherif, MD Professor & Vice Chair, Department of Medicine Director, Jefferson Women
More informationDiabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome
Diabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome John E. Nestler, M.D. William Branch Porter Professor of Medicine Chair, Department of Internal Medicine Virginia Commonwealth University
More informationDr Stella Milsom. Endocrinologist Fertility Associates Auckland. 12:30-12:40 When Puberty is PCO
Dr Stella Milsom Endocrinologist Fertility Associates Auckland 12:30-12:40 When Puberty is PCO Puberty or Polycystic Ovary Syndrome? Stella Milsom Endocrinologist Auckland DHB, University of Auckland,
More informationPrevalence of Polycystic Ovarian Syndrome among urban adolescent girls and young women in Mumbai
Prevalence of Polycystic Ovarian Syndrome among urban adolescent girls and young women in Mumbai Principal Investigator Co- Investigators Consultant Collaborating Hospital Dr. Beena Joshi Dr. Srabani Mukherji
More informationJMSCR Vol 04 Issue 12 Page December 2016
www.jmscr.igmpublication.org Impact Factor 5.244 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v4i12.103 Study of Effect of Metformin in PCOS
More information12/27/2013. Kristen Cain, MD FACOG Reproductive Medicine Institute Sanford Health, Fargo ND
Kristen Cain, MD FACOG Reproductive Medicine Institute Sanford Health, Fargo ND 7% of all women 18-45 Obesity 1/3 of all US women Incidence of PCOS is increasing with increase obesity Obesity Irregular
More informationDepartment of Obstetrics and Gynecology, University of Modena, Modena, Italy
FERTILITY AND STERILITY VOL. 81, NO. 1, JANUARY 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Metformin administration modulates
More informationInvestigation of adrenal functions in patients with idiopathic hyperandrogenemia
European Journal of Endocrinology (26) 155 37 311 ISSN 84-4643 CLINICAL STUDY Investigation of adrenal functions in patients with idiopathic hyperandrogenemia Hulusi Atmaca, Fatih Tanriverdi 1, Kursad
More informationThe Pharmacology of PCOS
The Pharmacology of PCOS G. Wright Bates, Jr., M.D. Director Reproductive Endocrinology & Infertility University of Alabama at Birmingham Objectives Review the diagnosis of PCOS Highlight lifestyle modifications
More informationASSOCIATION OF INSULIN RESISTANCE AND SERUM 25 OH VITAMIN-D IN INDIAN WOMEN WITH POLYCYSTIC OVARY SYNDROME
RESEARCH ARTICLE ASSOCIATION OF INSULIN RESISTANCE AND SERUM 25 OH VITAMIN-D IN INDIAN WOMEN WITH POLYCYSTIC OVARY SYNDROME Amar Nagesh Kumar 1, Jupalle Nagaiah Naidu 2, Uppala Satyanarayana 3, Medabalmi
More informationFeedback inhibition of insulin secretion and insulin resistance in polycystic ovarian syndrome with and without obesity
European Review for Medical and Pharmacological Sciences 1997; 1: 17-171 Feedback inhibition of insulin secretion and insulin resistance in polycystic ovarian syndrome with and without obesity d. sinagra,
More informationWhat every dermatologist should know about Polycystic Ovary Syndrome (PCOS)
What every dermatologist should know about Polycystic Ovary Syndrome (PCOS) Kanade Shinkai, MD PhD University of California, San Francisco Associate Professor of Dermatology I have no conflicts of interest
More informationReproductive outcome in women with body weight disturbances
Reproductive outcome in women with body weight disturbances Zeev Shoham M.D. Dep. Of OB/GYN Kaplan Hospital, Rehovot, Israel Weight Status BMI (kg/m 2 ) Underweight
More informationX/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Copyright 2006 by The Endocrine Society doi: /jc.
0021-972X/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Printed in U.S.A. Copyright 2006 by The Endocrine Society doi: 10.1210/jc.2005-1457 EXTENSIVE CLINICAL EXPERIENCE Relative
More informationA practical approach to the diagnosis of polycystic ovary syndrome
American Journal of Obstetrics and Gynecology (2004) 191, 713 7 www.elsevier.com/locate/ajog CLINICAL OPINION A practical approach to the diagnosis of polycystic ovary syndrome R. Jeffrey Chang, MD Department
More informationPolycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks
Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Kate D. Schoyer, M.D. May 6, 2016 Objectives To review how to make the diagnosis of Polycystic Ovarian Syndrome (PCOS)
More informationINSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME An Overview
INSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME An Overview University of PNG School of Medicine & Health Sciences Division of Basic Medical Sciences PBL MBBS III VJ Temple 1 Insulin Resistance: What is
More informationThe prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria
Prace oryginalne/original papers Endokrynologia Polska/Polish Journal of Endocrinology Tom/Volume 62; Numer/Number 3/2011 ISSN 0423 104X The prevalence of polycystic ovary syndrome in Iranian women based
More informationThe Impact of Insulin Resistance on Long-Term Health in PCOS
Saturday, April 16 th, 2016 PCOS Challenge & Thomas Jefferson University PCOS Awareness Symposium Philadelphia The Impact of Insulin Resistance on Long-Term Health in PCOS Katherine Sherif, MD Professor
More information-INOSITOL IN LEAN WOMEN WITH THE POLYCYSTIC OVARY SYNDROME
Original Article EFFECTS OF D-CHIRO-INOSITOL IN LEAN WOMEN WITH THE POLYCYSTIC OVARY SYNDROME Maria J. Iuorno, MD, 1 Daniela J. Jakubowicz, MD, 2 Jean-Patrice Baillargeon, MD, 3 Pamela Dillon, BS, 4 Ronald
More informationPOLYCYSTIC OVARIAN SYNDROME Laura Tatpati, MD Reproductive Endocrinology and Infertility. Based on: ACOG No. 108 Oct 2009; reaffirmed 2015
POLYCYSTIC OVARIAN SYNDROME Laura Tatpati, MD Reproductive Endocrinology and Infertility Based on: ACOG No. 108 Oct 2009; reaffirmed 2015 NO DISCLOSURES PATIENT 26 years old presents with complaint of
More informationMetfornim and Pioglitazone in polycystic ovarian syndrome: A comparative study
Original Research Article Metfornim and Pioglitazone in polycystic ovarian syndrome: A comparative study Allanki Suneetha Devi 1, Jalem Anuradha 2* 1 Associate Professor, Department of Obstetrics and Gynecology,
More informationCase. 24 year old female presented to your office complaining of excess hair growth on her face and abdomen. Questions?
Hirsutism Case 24 year old female presented to your office complaining of excess hair growth on her face and abdomen Questions? Started around puberty with gradual progression Irregular menstrual cycle
More informationAbnormal Uterine Bleeding Case Studies
Case Study 1 Abnormal Uterine Bleeding Case Studies Abigail, a 24 year old female, presents to your office complaining that her menstrual cycles have become a problem. They are now lasting 6 7 days instead
More informationWEIGHT CHANGE AND ANDROGEN LEVELS DURING CONTRACEPTIVE TREATMENT OF WOMEN AFFECTED BY POLYCYSTIC OVARY
ENDOCRINE REGULATIONS, VOL. 40, 119-123, 2006 119 WEIGHT CHANGE AND ANDROGEN LEVELS DURING CONTRACEPTIVE TREATMENT OF WOMEN AFFECTED BY POLYCYSTIC OVARY J. VRBIKOVA, K. DVORAKOVA, M. HILL, L. STARKA Institute
More informationOverview of Reproductive Endocrinology
Overview of Reproductive Endocrinology I have no conflicts of interest to report. Maria Yialamas, MD Female Hypothalamic--Gonadal Axis 15 4 Hormone Secretion in the Normal Menstrual Cycle LH FSH E2, Progesterone,
More informationThe Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (1), Page 63-69
The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (1), Page 63-69 Effect of Metformin Only versus Effect of Metformin and Corticosteroids after Laparoscopic Ovarian Drilling on Ovulation
More informationPCOS guidelines: What s relevant to general practice
PCOS guidelines: What s relevant to general Dr David Molloy Medical Director, Queensland Fertility Group International evidence based PCOS guidelines 1st ever internationally endorsed & evidence based
More informationPolycystic Ovarian Syndrome. Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology
Polycystic Ovarian Syndrome Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology Outline Definition Symptoms Causal factors Diagnosis Complications Treatment Why are we talking about
More informationPolycystic ovary syndrome
OBG MANAGEMENT COVER ARTICLE Polycystic ovary syndrome 3 key challenges BY DALE W. STOVALL, MD Newer findings have broadened options for medical management of insulin resistance, anovulation, and hyperandrogenism.
More informationProf.Dr. Nabil Lymon Head of Internal Medicine Department
By Prof.Dr. Nabil Lymon Head of Internal Medicine Department Definitions: Hirsutism: Is the presence of terminal hair in androgendependent sites where hair does not normally grow in women. This hair growth
More informationPolycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks. Kate D. Schoyer, M.D. May 6, 2016
Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Kate D. Schoyer, M.D. May 6, 2016 Objectives To review how to make the diagnosis of Polycystic Ovarian Syndrome (PCOS)
More informationJannet Huang, MD, FRCPC, FACE, ABIHM, CCD, NCMP.
Jannet Huang, MD, FRCPC, FACE, ABIHM, CCD, NCMP. Polycystic Ovarian Syndrome Definition & Diagnosis Clinical Significance: Link to Diabetes and Cardiovascular Risk Management Lifestyle Strategies Pharmacologic
More informationPCOS and Obesity DUB is better treated by OCPs
PCOS and Obesity DUB is better treated by OCPs Dr. Ritu Joshi Senior consultant Fortis escorts Hospital, Jaipur Chairperson Family welfare com. FOGSI (20092012) Vice President FOGSI 2014 Introduction One
More informationClinical Profile Polycystic Ovarian Syndrome Cases
ORIGINAL RESEARCH www.ijcmr.com - 100 Cases Himabindu Sangabathula 1, Neelima Varaganti 1 ABSTRACT Introduction: Polycystic ovary syndrome (PCOS) is most common endocrine disorders of reproductive age
More informationComparative study of metabolic profile of women presenting with polycystic ovary syndrome in relation to body mass index
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Akshaya S et al. Int J Reprod Contracept Obstet Gynecol. 2016 Aug;5(8):2561-2565 www.ijrcog.org pissn 2320-1770 eissn 2320-1789
More informationEndocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound
Human Reproduction vol.12 no.5 pp. 905 909, 1997 Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound E.Carmina 1, L.Wong 2, L.Chang 2, R.J.Paulson 2, disturbance of the IGF/IGFBP-l
More informationDoppler flow velocities of uterine and ovarian arteries & hormonal patterns in patients with Polycystic Ovary Syndrome (PCOS)
Original article: Doppler flow velocities of uterine and ovarian arteries & hormonal patterns in patients with Polycystic Ovary Syndrome (PCOS) Dr. Deepali Dhingra*#, Dr. Shashi Prateek*, Dr. Renuka Sinha*,
More informationNorth Carolina Center for Reproductive Medicine, Cary, North Carolina
FERTILITY AND STERILITY VOL. 75, NO. 3, MARCH 2001 Copyright 2001 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Metformin treatment
More informationThe New England Journal of Medicine OVULATORY AND METABOLIC EFFECTS OF D-CHIRO-INOSITOL IN THE POLYCYSTIC OVARY SYNDROME
OVULATORY AND METABOLIC EFFECTS OF D-CHIRO-INOSITOL IN THE POLYCYSTIC OVARY SYNDROME JOHN E. NESTLER, M.D., DANIELA J. JAKUBOWICZ, M.D., PAULA REAMER, M.A., RONALD D. GUNN, M.S., AND GEOFFREY ALLAN, PH.D.
More informationInsulin, androgens, and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders
FERTILITY AND STERILITY VOL. 72, NO. 1, JULY 1999 Copyright 1999 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Insulin, androgens, and
More informationJMSCR Vol 05 Issue 04 Page April 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i4.228 Study of Cutaneous Manifestations of
More informationNew PCOS guidelines: What s relevant to general practice
New PCOS guidelines: What s relevant to general practice Dr Michael Costello Fertility Specialist IVF Australia UNSW Royal Hospital for Women Sydney How do we know if something is new? Louvre Museum, Paris
More informationHyperinsulinemia is common in family members of women with polycystic ovary syndrome*
FERTILITY AND STERILITY Vol. 66, No.6, December 1996 Copyright 1996 American Society for Reproductive Medicine Printed on acid~free paper in U. S. A. Hyperinsulinemia is common in family members of women
More informationObjectives 1. Be able to describe the classic presentation and diagnostic criteria 2. Be able to explain long-term health concerns associated with the diagnosis 3. Understand what basic treatment options
More informationAssisted Reproductive. Technologies: Present and. Future
Assisted Reproductive Technologies: Present and Future Paul Kaplan, M.D. The Assisted Reproductive Technologies (ART) In Vitro Fertilization (IVF) Intracytoplasmic Sperm Injection (IVF/ICSI) Donor Oocyte
More informationPolycystic Ovary (Stein-Leventhal) Syndrome: Etiology, Complications, and Treatment
REPORTS AND REVIEWS Polycystic Ovary (Stein-Leventhal) Syndrome: Etiology, Complications, and Treatment KARRI LYNN HOYT, MARGARET C SCHMIDT Polycystic ovary syndrome (PCOS) occurs in approximately 3% to
More informationSyndrome in Clinical Practice
Focus on CME at the University of British Columbia Polycystic Ovarian Syndrome in Clinical Practice Although polycystic ovarian syndrome was first recognized and described more than 60 years ago, the primary
More informationREDUCING SERUM INSULIN AND OVARIAN CYTOCHROME P450c17a IN POLYCYSTIC OVARY SYNDROME
REDUCING SERUM INSULIN AND OVARIAN CYTOCHROME P45c17a IN POLYCYSTIC OVARY SYNDROME DECREASES IN OVARIAN CYTOCHROME P45c17a ACTIVITY AND SERUM FREE TESTOSTERONE AFTER REDUCTION OF INSULIN SECRETION IN POLYCYSTIC
More informationOutlook PCOS: a diagnostic challenge
RBMOnline - Vol 8. No 6. 2004 644-648 Reproductive BioMedicine Online; www.rbmonline.com/article/1274 on web 5 April 2004 Outlook PCOS: a diagnostic challenge Dr Ricardo Azziz Dr Azziz is currently Chairman
More informationResearch Article. Ramanand SJ 1, Raparti GT 2 *, Halasawadekar NR 1, Ramanand JB 3, Kumbhar AV 1, Shah RD 1
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Ramanand SJ et al. Int J Reprod Contracept Obstet Gynecol. 2016 Sept;5(9):3181-3185 www.ijrcog.org pissn 2320-1770 eissn
More informationAnovulatory Infertility: A Prospective Study
10.5005/jp-journals-10016-1055 Geetu Bhandoria, Samar Rudra RESEARCH ARTICLE Geetu Bhandoria, Samar Rudra ABSTRACT Introduction: Anovulation is a common cause of infertility with poly cystic ovarian disease
More informationUniversity of Cape Town
P a g e 1 The Polycystic Ovary Syndrome a comparison of the presentation in adolescents compared to women aged 35 years and older attending the Gynaecological Endocrine clinic at Groote Schuur Hospital.
More informationCan high serum anti-müllerian hormone levels predict the phenotypes of polycystic ovary syndrome (PCOS) and metabolic disturbances in PCOS patients?
ORIGINAL ARTICLE http://dx.doi.org/1.5653/cerm.213.4.3.135 pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 213;4(3):135-14 Can high serum anti-müllerian hormone levels predict the phenotypes of polycystic
More informationPCOS IN ADOLESCENTS: EARLY DETECTION AND INTERVENTION
PCOS IN ADOLESCENTS: EARLY DETECTION AND INTERVENTION R A C H A N A S H A H, M D M S T R A S S I S TA N T P R O F E S S O R O F P E D I AT R I C S D I V I S I O N O F E N D O C R I N O L O G Y A N D D
More informationClinical and biochemical presentation of polycystic ovary syndrome in women between the ages of 20 and 40
Human Reproduction, Vol.26, No.12 pp. 3443 3449, 2011 Advanced Access publication on September 16, 2011 doi:10.1093/humrep/der302 ORIGINAL ARTICLE Reproductive endocrinology Clinical and biochemical presentation
More informationAbdulrahim A. Rouzi, FRCSC, a and Mohammed Salleh M. Ardawi, Ph.D., F.R.C.Path. b
A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate resistant polycystic ovary syndrome Abdulrahim
More informationMETABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN MORPHOLOGY
Vuk Vrhovac University Clinic Dugi dol 4a, HR-10000 Zagreb, Croatia Original Research Article Received: February 18, 2010 Accepted: March 3, 2010 METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN
More informationPCOS. Reproductive Gynaecology and Infertility. Dr.Renda Bouzayen MD.FRCSC GREI,OBGYN Dalhousie University
Reproductive Gynaecology and Infertility PCOS Dr.Renda Bouzayen MD.FRCSC GREI,OBGYN Dalhousie University Dr.Hussein Sabban MD. FRCSC PGY6 GREI Dalhousie University Disclosure No conflict of interest Pilot
More informationclinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome
& clinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome Zulfo Godinjak¹*, Ranka Javorić² 1 Gynecology and Obstetrics
More informationPrevalence of polycystic ovarian syndrome in the Buraimi region of Oman
Original Article Brunei Int Med J. 2012; 8 (5): 248-252 Prevalence of polycystic ovarian syndrome in the Buraimi region of Oman Usha VARGHESE 1 and Shaji VARUGHESE 2, 1 Department of Internal Medicine
More informationFemale Reproductive Endocrinology
Female Reproductive Endocrinology Dr. Channa Jayasena PhD MRCP FRCPath Clinical Senior Lecturer & Consultant Endocrinologist Department of Gynaecology, Hammersmith Hospital Anovulation is a common cause
More informationPrevalence of polycystic ovarian changes and polycystic ovary syndrome in premenopausal women with treated type 2 diabetes mellitus
Prevalence of polycystic ovarian changes and polycystic ovary syndrome in premenopausal women with treated type 2 diabetes mellitus Fahrettin Kelestimur, M.D., a Kürşad Unluhizarci, M.D., a Hür Baybuga,
More informationTHE PREVALENCE AND ETIOLOGY OF POLYCYSTIC OVARIAN SYNDROME (PCOS) AS A CAUSE OF FEMALE INFERTILITY IN CENTRAL TRAVANCORE
NSave Nature to Survive 9(1): 01-06, 2014 www.thebioscan.in THE PREVALENCE AND ETIOLOGY OF POLYCYSTIC OVARIAN SYNDROME (PCOS) AS A CAUSE OF FEMALE INFERTILITY IN CENTRAL TRAVANCORE K. ROY GEORGE AND N.
More informationTitle of Guideline (must include the word Guideline (not protocol, policy, procedure etc)
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Guideline for the Investigation and Management of Polycystic Ovary Syndrome Author: Contact Name and Job Title
More informationAmenorrhoea: polycystic ovary syndrome
There is so much we don't know in medicine that could make a difference, and often we focus on the big things, and the little things get forgotten. To highlight some smaller but important issues, we've
More informationX/03/$20.00/0 Endocrine Reviews 24(5): Copyright 2003 by The Endocrine Society doi: /er
0163-769X/03/$20.00/0 Endocrine Reviews 24(5):633 667 Printed in U.S.A. Copyright 2003 by The Endocrine Society doi: 10.1210/er.2002-0015 Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome
More informationCARDIOVASCULAR EVENTS IN POLYCYSTIC OVARY SYNDROME
CARDIOVASCULAR EVENTS IN POLYCYSTIC OVARY SYNDROME Enrico Carmina Executive Director & CEO of Androgen Excess & PCOS Society Professor of Endocrinology Department of Health Sciences and Mother and Child
More informationWhat is PCOS? PCOS THE CONQUER PCOS E-BOOK. You'll be amazed when you read this...
PCOS What is PCOS? You'll be amazed when you read this... What is PCOS?. Who is at risk? How to get tested? What are the complications. Is there a cure? What are the right ways to eat? What lifestyle changes
More informationInfertility for the Primary Care Provider
Infertility for the Primary Care Provider David A. Forstein, DO FACOOG Clinical Associate Professor Obstetrics and Gynecology University of South Carolina School of Medicine Greenville Disclosure I have
More information